Key Takeaways
- The Phase 2 retatrutide trial (Jastreboff et al., NEJM 2023, n=338) showed approximately 24.2% mean weight loss at 48 weeks in the 12 mg weekly group, the largest reduction reported for any obesity drug at that time point.
- Retatrutide is a triple receptor agonist targeting GIP, GLP-1, and glucagon receptors in a single peptide molecule, distinguishing it mechanistically from dual agonists like tirzepatide.
- Phase 3 trials are ongoing as of 2026; retatrutide is not FDA-approved and no legal compounded version exists for human use outside a registered clinical trial.
- Gastrointestinal adverse events drove most discontinuations in Phase 2; a mean heart rate increase of approximately 4 to 6 bpm at high doses reflects glucagon receptor engagement and requires monitoring.
- The half-life of approximately 6 days, achieved via a C18 fatty diacid albumin-binding modification, enables once-weekly subcutaneous injection, the same dosing schedule used in Phase 2.
What Is the Reta Peptide Clinical Trial?
The reta peptide clinical trial refers primarily to the Eli Lilly Phase 2 study of retatrutide (LY3437943), a synthetic triple-receptor agonist. The landmark Phase 2 results were published by Jastreboff et al. in the New England Journal of Medicine in 2023. In that 48-week, randomized, placebo-controlled trial of 338 adults with obesity, participants on the highest dose (12 mg weekly) lost a mean of approximately 24.2% of body weight, with a placebo-corrected difference not previously seen in an obesity pharmacotherapy trial of that duration.
- How does retatrutide work at the receptor level?
- What did the Phase 2 clinical trial actually show?
- Evidence ledger: grading every major claim
- What most pages get wrong about the reta peptide
- Why does the C18 modification matter? The chemistry behind the half-life
- Honest head-to-head: retatrutide vs. tirzepatide vs. semaglutide
- What side effects appeared in clinical trials?
- What Phase 3 trials are running and when will results arrive?
- Operational guide: how to evaluate any retatrutide product or protocol
- FAQ
- Sources
How Does Retatrutide Work at the Receptor Level?
Retatrutide co-activates three G-protein-coupled receptors simultaneously, a structural feat achieved in a single peptide backbone with engineered binding domains for each target:
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →- GLP-1R (glucagon-like peptide-1 receptor): Slows gastric emptying, suppresses appetite via hypothalamic signaling, and stimulates glucose-dependent insulin secretion. This mechanism is shared with semaglutide and tirzepatide.
- GIPR (glucose-dependent insulinotropic polypeptide receptor): Enhances insulin secretion and may reduce the nausea associated with pure GLP-1R agonism. This target is also engaged by tirzepatide.
- GCGR (glucagon receptor): The distinguishing target. Glucagon receptor agonism increases hepatic fatty acid oxidation, raises resting energy expenditure, and promotes lipolysis. In isolation, glucagon raises blood glucose; combined with GLP-1R agonism the glucose-raising effect is blunted while the metabolic benefits are preserved.
The honest caveat: demonstrating receptor binding in vitro and even weight loss in a clinical trial does not prove which receptor contributes what fraction of the clinical effect in humans. Mechanistic attribution across three targets in a living system remains an area of active research.
What Did the Phase 2 Clinical Trial Actually Show?
The Jastreboff et al. 2023 trial enrolled adults with a BMI of 30 or above (or 27 or above with at least one weight-related condition) but without type 2 diabetes. Key results:
| Dose Group | n (approximate) | Mean Weight Change at 48 Weeks | GI Discontinuation Rate |
|---|---|---|---|
| Placebo | 70 | Approximately minus 2.1% | Low |
| 1 mg weekly | 45 | Approximately minus 8.7% | Low |
| 4 mg weekly | 45 | Approximately minus 17.3% | Moderate |
| 8 mg weekly | 45 | Approximately minus 22.8% | Higher |
| 12 mg weekly | 45 | Approximately minus 24.2% | Approximately 16% |
Weight loss curves had not plateaued at 48 weeks in the higher dose groups, suggesting continued response with longer treatment. Fasting glucose, triglycerides, and waist circumference improved across all active groups in a dose-dependent manner. These are Phase 2 signals, not confirmatory Phase 3 outcomes.
Evidence Ledger: Grading Every Major Claim
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| Retatrutide produces substantial weight loss in adults with obesity | Phase 2 RCT (n=338, 48 weeks) | Strong reduction, dose-dependent | Moderate |
| Triple agonism (GIP+GLP-1+glucagon) is the mechanism | Pharmacology + in vitro binding + Phase 2 PK/PD | Consistent with data | Moderate |
| Glucagon receptor engagement raises energy expenditure | Animal studies + mechanistic inference | Directionally supported | Low (in humans at these doses) |
| GI adverse events are the main tolerability issue | Phase 2 RCT safety data | Confirmed, dose-related | High |
| Heart rate increase at high doses | Phase 2 RCT (mean approximately 4 to 6 bpm increase noted) | Small but consistent increase | Moderate |
| Superiority to tirzepatide or semaglutide for weight loss | Indirect comparison only; no head-to-head RCT | Numerically favors retatrutide in Phase 2 vs. Phase 3 peers | Very Low |
| Long-term cardiovascular safety | Not yet studied; Phase 3 ongoing | Unknown | Very Low |
| Thyroid C-cell risk (class concern from animal data) | Rodent carcinogenicity data for GLP-1 class; no human signal yet | Unknown in humans | Very Low |
What Most Pages Get Wrong About the Reta Peptide
1. Phase 2 is not Phase 3. The 338-person, 48-week trial generated hypothesis-confirming signals, not regulatory-grade evidence. Effect sizes from Phase 2 trials frequently shrink in larger, more diverse Phase 3 populations. The 24.2% figure is impressive and real, but it is not a confirmed outcome across the population that would receive a licensed drug.
2. Retatrutide cannot be accurately replicated in a small-batch peptide synthesis facility. The molecule requires a C18 fatty diacid side chain attached at a specific lysine residue, plus careful control of disulfide bridges and alpha-helical secondary structure. Small-scale synthesis errors at any step produce a structurally different molecule. Vendors selling "reta peptide" as a research compound cannot credibly guarantee they have the correct molecule, let alone sterility and endotoxin levels safe for injection.
3. "Not yet plateau" cuts both ways. Presentations at obesity conferences emphasized that the weight loss curve had not flattened at 48 weeks. Some readers interpret this as proof of even greater long-term efficacy. The alternative reading is that late-emerging adverse events had not fully manifested either. Phase 3 duration matters for both efficacy and safety characterization.
4. The glucagon component raises blood glucose independently. In patients with type 2 diabetes, the GCGR agonism requires careful titration to avoid hyperglycemia. The Phase 2 study excluded type 2 diabetes. Extrapolating the weight loss data to diabetic populations without Phase 3 evidence is scientifically unsound.
5. "Reta peptide" in vendor listings is a marketing shorthand, not a pharmacopoeial name. The INN is retatrutide. Searching for "reta peptide" on research chemical sites and assuming regulatory equivalence to the Eli Lilly compound is a category error.
Why Does the C18 Modification Matter? The Chemistry Behind the Half-Life
Unmodified GLP-1 has a plasma half-life of roughly 2 minutes due to rapid cleavage by dipeptidyl peptidase-4 (DPP-4) and renal filtration. Retatrutide's approximately 6-day half-life is achieved through a C18 fatty diacid chain attached to a specific lysine residue in the peptide backbone. The mechanism is non-covalent, reversible binding to circulating albumin (serum albumin has a half-life of approximately 19 days). When bound to albumin, retatrutide is too large for glomerular filtration and is shielded from DPP-4 cleavage. It slowly equilibrates to the free form, which binds receptors, and then rebinds albumin.
Why this matters for product evaluation: a research compound vendor who synthesizes the correct peptide sequence but attaches the wrong fatty acid chain, or attaches it at the wrong lysine residue, will produce a molecule with a dramatically shorter half-life, different receptor affinity, and likely reduced efficacy. There is no visual way to confirm this from a product photograph or even a basic HPLC purity certificate. Mass spectrometry confirming both sequence and modification site is the minimum analytical standard.
Storage also matters: the fatty acid chain makes the molecule more susceptible to oxidation of methionine residues in the backbone than shorter unmodified peptides. Improper storage (freeze-thaw cycling, exposure to light) degrades the molecule in ways that reduce potency without necessarily changing gross appearance. A degraded solution can look identical to a potent one.
Honest Head-to-Head: Retatrutide vs. Tirzepatide vs. Semaglutide
| Feature | Retatrutide | Tirzepatide | Semaglutide 2.4 mg |
|---|---|---|---|
| Receptor targets | GIP + GLP-1 + Glucagon | GIP + GLP-1 | GLP-1 only |
| Best trial weight loss | Approx. 24.2% (Phase 2, 48 wk) | Approx. 20.9% (Phase 3, 72 wk) | Approx. 14.9% (Phase 3, 68 wk) |
| Trial phase (obesity) | Phase 2 complete; Phase 3 ongoing | Phase 3 complete; FDA-approved | Phase 3 complete; FDA-approved |
| FDA approval (obesity) | No | Yes (Zepbound, 2023) | Yes (Wegovy, 2021) |
| Dosing frequency | Once weekly (SC) | Once weekly (SC) | Once weekly (SC) |
| Half-life | Approximately 6 days | Approximately 5 days | Approximately 7 days |
| GI tolerability | Moderate to high nausea/vomiting in Phase 2 | Moderate; less than semaglutide in some analyses | Moderate; dose-dependent |
| Heart rate effect | Small increase (glucagon-mediated) | Small increase | Small increase |
| Long-term CV outcomes data | None yet | SURPASS-CVOT ongoing | SELECT trial: 20% CV event reduction |
| Legal availability | Clinical trial only | Commercial Rx; compounded versions regulated | Commercial Rx; compounded versions regulated |
| Where retatrutide LOSES | No approval, no long-term safety data, no CV outcomes proof, not accessible | Mature safety profile, commercial access | SELECT CV data is a unique strength |
The honest judgment: retatrutide's Phase 2 efficacy signal is genuinely exciting and numerically larger than approved alternatives. But Phase 2 versus Phase 3 comparisons across different trial populations and durations are indirect. Semaglutide currently has the only published major cardiovascular outcomes trial for a GLP-1-class obesity drug (SELECT, 2023). That is a clinical advantage retatrutide cannot claim yet.
What Side Effects Appeared in Clinical Trials?
From the Jastreboff et al. Phase 2 data:
- Nausea: Most common, especially during dose escalation periods. Rate was higher than placebo across all active groups.
- Vomiting and diarrhea: Reported in a meaningful minority; consistent with the GLP-1 class effect on gastric motility.
- Constipation: Also noted, reflecting slowed GI transit at stable doses.
- Heart rate increase: A mean increase of approximately 4 to 6 bpm observed at higher doses. This is attributed to glucagon receptor-mediated chronotropy. The clinical significance for patients with pre-existing arrhythmias is unknown from Phase 2 data alone.
- Injection site reactions: Reported in a minority; typical for subcutaneous peptide injections.
- Discontinuations due to adverse events: Approximately 16% in the 12 mg group, predominantly GI-related.
What Phase 3 Trials Are Running and When Will Results Arrive?
Eli Lilly initiated the TRIUMPH Phase 3 program for retatrutide. Registered trials on ClinicalTrials.gov cover:
- Obesity without type 2 diabetes (primary efficacy and safety trial)
- Type 2 diabetes with obesity
- Obstructive sleep apnea
- Cardiovascular risk reduction (long-term outcomes)
Top-line Phase 3 obesity data was anticipated in 2025 to 2026 based on enrollment timelines disclosed at industry conferences. No Phase 3 results have been published in a peer-reviewed journal as of the date of this page. When Phase 3 data becomes available, the evidence confidence ratings on this page will be updated. Regulatory submission to the FDA would follow positive Phase 3 results, typically with a review period of 6 to 12 months.
Operational Guide: How to Evaluate Any Retatrutide Product or Protocol
Because retatrutide is not commercially available, any product presented as "reta peptide" for use outside a registered clinical trial warrants a high level of skepticism. Here is how to evaluate claims:
| What to Check | Minimum Standard | Red Flag |
|---|---|---|
| Peptide identity | Mass spec (LCMS) confirming sequence AND fatty acid modification site | HPLC purity only; no sequence confirmation |
| Purity certificate | Greater than 98% purity by HPLC from an independent third-party lab | In-house testing only; no lab name or chromatogram |
| Sterility and endotoxin | USP-compliant sterility and LAL endotoxin test for any injectable compound | No endotoxin data; freeze-dried vials with no sterility documentation |
| Storage conditions | Lyophilized: stable at minus 20 degrees C for months; avoid repeated freeze-thaw. Reconstituted: refrigerate and use within a short window | "Room temperature stable" claims for a reconstituted solution |
| Dosing claims | Reference the Jastreboff et al. Phase 2 dose escalation schedule; no approved human dose exists | Vendor-specified "optimal dose" with no clinical reference |
| Legal status | For research use only; not for human administration outside an IRB-approved trial | Any vendor suggesting it is equivalent to a licensed product or safe for self-injection |
If you are seeking access to retatrutide legally, the only pathway is enrollment in a registered clinical trial. ClinicalTrials.gov allows free searching by condition (obesity), intervention (retatrutide or LY3437943), and geographic location.
FAQ
What is the reta peptide and what clinical trials have studied it?
Reta peptide most commonly refers to retatrutide (LY3437943), a GIP, GLP-1, and glucagon triple-receptor agonist developed by Eli Lilly. A Phase 2 trial published in the New England Journal of Medicine in 2023 (Jastreboff et al.) showed mean body weight reduction of approximately 17.5% at 24 weeks and approximately 24.2% at 48 weeks in adults with obesity. Phase 3 trials are ongoing as of 2026.
How does retatrutide work at the receptor level?
Retatrutide co-activates three receptors in a single peptide molecule: the GIPR, GLP-1R, and GCGR. Triple agonism adds glucagon-driven hepatic fat oxidation and increased energy expenditure on top of the appetite suppression and insulin sensitization seen with dual GIP and GLP-1 agonists like tirzepatide.
What were the Phase 2 clinical trial results for retatrutide?
In the Jastreboff et al. 2023 NEJM Phase 2 trial (338 participants, 48 weeks), the highest dose group (12 mg weekly) achieved mean weight loss of approximately 24.2% from baseline. Placebo participants lost approximately 2.1%. Discontinuation due to adverse events occurred in roughly 16% of the highest-dose group, primarily from gastrointestinal side effects.
Is retatrutide approved by the FDA?
No. As of May 2026, retatrutide is not FDA-approved. It is in Phase 3 clinical trials. Any product marketed as "reta peptide" for human use outside a clinical trial is unapproved and carries unverified purity and safety risks.
How does retatrutide compare to tirzepatide and semaglutide for weight loss?
Phase 2 retatrutide data (approximately 24% weight loss at 48 weeks) appears to exceed Phase 3 tirzepatide data (approximately 20.9% at 72 weeks, SURMOUNT-1) and semaglutide 2.4 mg (approximately 14.9% at 68 weeks, STEP 1). No direct head-to-head trial has been conducted; indirect comparisons must be made with caution.
What are the main side effects of retatrutide seen in clinical trials?
Nausea, vomiting, diarrhea, and constipation dominated Phase 2 adverse event data, especially during dose escalation. A mean heart rate increase of approximately 4 to 6 bpm at higher doses reflects glucagon receptor engagement. No unexpected safety class signals emerged in Phase 2.
What does the reta peptide clinical trial tell us about long-term safety?
The Phase 2 trial ran to 48 weeks, which is insufficient to characterize thyroid C-cell effects (a class concern from animal data), pancreatitis, or cardiovascular outcomes. Phase 3 trials with larger populations and longer follow-up are required before long-term safety can be established.
Can retatrutide be obtained as a research compound or compounded peptide?
Retatrutide requires a specific C18 fatty acid modification at a defined lysine residue for correct pharmacokinetics. Small-scale synthesis cannot reliably reproduce this. Research-grade versions sold online carry risks of incorrect structure, low purity, and absent sterility testing. No compounded version is legal for human use in the US outside a registered trial.
What is the half-life of retatrutide and how is it dosed in trials?
Retatrutide has a half-life of approximately 6 days via albumin binding through its C18 fatty diacid modification. This supports once-weekly subcutaneous dosing. Phase 2 used dose groups of 1 mg, 4 mg, 8 mg, and 12 mg weekly, with a structured escalation to reduce GI adverse events.
What Phase 3 trials are currently running for retatrutide?
Eli Lilly's TRIUMPH Phase 3 program covers obesity, type 2 diabetes, obstructive sleep apnea, and cardiovascular risk reduction. Phase 3 obesity results were anticipated in 2025 to 2026. Trials are searchable on ClinicalTrials.gov under retatrutide or LY3437943.
Why do some sources call it "reta peptide" instead of retatrutide?
"Reta peptide" is informal shorthand used on patient forums and in some compounding vendor listings. The INN is retatrutide. Using informal names in a commercial context can obscure regulatory and safety status from consumers and should be treated as a caution signal.
Sources
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-hormone-receptor agonist retatrutide for obesity: a Phase 2 trial. New England Journal of Medicine. 2023;389(6):514-526. PMID: 37486780.
- Ludvik B, Frías JP, Tinahones FJ, et al. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10). Lancet Diabetes Endocrinol. 2018 (cited for GLP-1 class mechanism context).
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205-216.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. 2023;389(24):2221-2232.
- Drucker DJ. The biology of incretin hormones. Cell Metabolism. 2006;3(3):153-165.
- ClinicalTrials.gov. Eli Lilly retatrutide (LY3437943) Phase 3 TRIUMPH program. Searchable at clinicaltrials.gov.
- FDA. Zepbound (tirzepatide) Prescribing Information. November 2023.
- FDA. Wegovy (semaglutide) Prescribing Information. June 2021.
- Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Frontiers in Endocrinology. 2019;10:155. (Albumin-binding fatty acid modification pharmacology context.)